Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure

Previous studies have shown that an epidermal growth factor‐based formulation (Heberprot‐P) can enhance granulation of high‐grade diabetic foot ulcers (DFU). The aim of this study was to explore the clinical effects of this administration up to complete wound closure. A pilot study in 20 diabetic patients with full‐thickness lower extremity ulcers of more than 4 weeks of evolution was performed. Mean ulcer size was 16·3 ± 21·3 cm2. Intralesional injections of 75 μg of Heberprot‐P three times per week were given up to complete wound healing. Full granulation response was achieved in all 20 patients in 23·6 ± 3·8 days. Complete wound closure was obtained in 17 (85%) cases in 44·3 ± 8·9 days. Amputation was not necessary in any case and only one relapse was notified. The most frequent adverse events were tremors, chills, pain and ardour at site of administration and local infection. The therapeutic scheme of intralesional Heberprot‐P administration up to complete closure can be safe and suitable to improve the therapeutic goal in terms of healing of chronic DFU.

[1]  D. Armstrong,et al.  A Supplement to : Foot & Ankle Surgery , 2006 .

[2]  David G Armstrong,et al.  Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. , 2001, Diabetes care.

[3]  D. Margolis,et al.  Effectiveness of recombinant human platelet‐derived growth factor for the treatment of diabetic neuropathic foot ulcers , 2005, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[4]  P. López-Saura,et al.  Intralesional injections of Citoprot‐P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation , 2007, International wound journal.

[5]  A. Boulton,et al.  Multicenter Study of the Incidence of and Predictive Risk Factors for Diabetic Neuropathic Foot Ulceration , 1998, Diabetes Care.

[6]  A. Boulton,et al.  The global burden of diabetic foot disease , 2005, The Lancet.

[7]  B. Humbel,et al.  The epidermal growth factor. , 1995, Cell biology international.

[8]  J. Griffiths,et al.  The North‐West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community‐based patient cohort , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[9]  Y. Kim,et al.  Recombinant Human Epidermal Growth Factor (EGF) to Enhance Healing for Diabetic Foot Ulcers , 2006, Annals of plastic surgery.

[10]  Jorge Amador Berlanga Acosta,et al.  Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds , 2006, International wound journal.

[11]  Paul G Scott,et al.  Pathophysiology of chronic nonhealing wounds. , 2005, The Journal of burn care & rehabilitation.

[12]  M. Tsang,et al.  Human epidermal growth factor enhances healing of diabetic foot ulcers. , 2003, Diabetes care.

[13]  Guidance for industry: Chronic cutaneous ulcer and burn wounds—developing products for treatment , 2001, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[14]  S. Cohen,et al.  Epidermal growth factor , 1972, The Journal of investigative dermatology.

[15]  Benjamin A Lipsky,et al.  Diagnosis and Treatment of Diabetic Foot Infections , 1988, Bailliere's best practice & research. Clinical rheumatology.

[16]  G. Schultz,et al.  Interactions of cytokines, growth factors, and proteases in acute and chronic wounds , 1996, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[17]  G. Schultz,et al.  Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[18]  G. Georgiadis,et al.  Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. , 2007, Journal of diabetes and its complications.

[19]  W. Marston,et al.  The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. , 2003, Diabetes care.

[20]  W. Eaglstein,et al.  The "trap" hypothesis of venous ulceration , 1993, The Lancet.